Recursion Pharmaceuticals, Inc. (RXRX) P/E Ratio, ROE & Key Statistics
$2.72NMS: RXRXMarket Cap $1.69B
Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)
Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Recursion Pharmaceuticals, Inc. (RXRX), each with what it measures. Figures are trailing twelve months or the most recent reported period.
Valuation
Metric
Value
P/E ratioShare price divided by earnings per share.
-4.09
P/B ratioShare price divided by book value per share.
2.21
P/S ratioMarket value divided by annual revenue.
32.19
PEG ratioP/E divided by the earnings growth rate.
-0.05
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.
-4.24
EV / RevenueEnterprise value against annual revenue.
25.23
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.
-25.25%
Free cash flow yieldFree cash flow as a percentage of market value.
-14.32%
Profitability
Metric
Value
Gross marginRevenue left after the direct cost of goods sold.
10.74%
Operating marginRevenue left after operating costs.
-725.44%
Net marginRevenue left after every cost, including tax and interest.
-697.13%
Return on equityProfit as a percentage of shareholders’ equity.
-47.85%
Return on assetsProfit as a percentage of total assets.
-38.93%
Return on capital employedOperating profit against the capital the business uses.
-45.05%
Financial health
Metric
Value
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.
5.01
Quick ratioThe same, excluding inventory.
5.01
Cash ratioCash alone against current liabilities.
5.02
Debt to equityTotal borrowings against shareholders’ equity.
0.08
Debt to assetsTotal borrowings against total assets.
0.05
Interest coverageHow many times operating profit covers the interest bill.
-751.11
Per share and size
Metric
Value
Earnings per shareProfit attributable to each share.
−$1.44
Book value per shareShareholders’ equity divided by shares outstanding.
$1.93
Market capitalisationShare price times shares outstanding.
$1.69B
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.
$1.51B
Dividend
Metric
Value
Dividend yieldAnnual dividend as a percentage of the share price.
0.00%
Recursion Pharmaceuticals, Inc. (RXRX) statistics — frequently asked questions
What is Recursion Pharmaceuticals, Inc.'s P/E ratio?
Recursion Pharmaceuticals, Inc. (RXRX) trades on a price-to-earnings ratio of -4.09. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.
What is Recursion Pharmaceuticals, Inc.'s return on equity?
Recursion Pharmaceuticals, Inc. (RXRX) reports a return on equity of -47.85%, meaning it generated that much profit for every dollar of shareholders' equity.
How much debt does Recursion Pharmaceuticals, Inc. carry?
Recursion Pharmaceuticals, Inc. (RXRX) has a debt-to-equity ratio of 0.08, which compares total borrowings with shareholders' equity.
What is Recursion Pharmaceuticals, Inc.'s profit margin?
Recursion Pharmaceuticals, Inc. (RXRX) keeps -697.13% of revenue as net profit after every cost, including tax and interest.